ziprasidone has been researched along with nateglinide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Goracci, L; Neri, A; Oprea, TI | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hussar, DA | 1 |
1 review(s) available for ziprasidone and nateglinide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for ziprasidone and nateglinide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
Topics: Animals; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Butyrophenones; Cell Line, Tumor; Cell Membrane Permeability; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Mice; Models, Molecular; Molecular Structure; Piperazines; Piperidines; Protein Binding; Quantitative Structure-Activity Relationship; Quinolones | 2011 |
New drugs 2002, part 1.
Topics: Amides; Aminosalicylic Acids; Anti-Ulcer Agents; Antipsychotic Agents; Bimatoprost; Cloprostenol; Cyclohexanes; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Galantamine; Glaucoma; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Mesalamine; Nateglinide; Nootropic Agents; Phenylalanine; Phenylhydrazines; Piperazines; Thiazoles; Travoprost | 2002 |